The vaccine Leader Moderna, a U.S. company is developing experimental vaccines against the coronavirus, signed a deal with Lonza Group AG for manufacturing 1 billion Covid-19 doses a year.
Both the companies announced a global agreement under which the Swiss chemical and pharmaceutical company will work up together to produce the proposed vaccine for coronavirus. The production is based on a novel technology that relies on genetic material called mRNA. The first batch of doses is expected to be produced in the U.S. in July.
On Thursday, AstraZeneca Plc announced an agreement to make an experimental coronavirus vaccine developed by the University of Oxford, eyeing production capacity for 100 million doses by the end of the year.
These experimental vaccines induce the body’s cells to make virus-like proteins that stimulate an immune response and prepare for an actual infection. The company said these vaccines were one of the first proposed coronavirus vaccines to enter human trials and they are planning to begin the next phase of studies this quarter.
Moderna shares have doubled since the start of the year. Moreover, the deal with Lonza will enable a tenfold increase in manufacturing, adding more rise in the share.
At the starting of the game, the smaller players won’t be able to produce a vaccine in large quantities on their own. Because of that Inovio Pharmaceuticals Inc. and other U.S. biotech companies agreed to expand their manufacturing collaboration with Germany’s Richter-Helm Biologics.
The possibilities of drugs to cure COVID-19 remain uncertain. But the entire world wants a solution for this global pandemic to set their countrymen free and reopen their economy. However, if Moderna and Lonza reach their target of 1 billion doses a year, that would be enough for more than one-eighth of the world’s population. So, they need to accelerate the process of bringing out a vaccine.